Agios Pharmaceuticals Inc - AGIO Net Assets per Single Share

Graphic logo of Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO) focuses on treating rare genetic pathologies, mitigating risks by divesting oncology assets to replenish reserves. However, global conflicts could disrupt component logistics and slow down international trials. This price chart demonstrates the stock's dynamics, where the key indicator equals 17.27. In the future, growth may be constrained by low revenue from a single product and potential research disruptions.

Agios (AGIO): Share Book Value from 07/04/2022 to 10/28/2026

agios.com - analytical breakdowns and key metrics (AGIO)

- price and consensus price forecast:
Stock Price Agios Pharmaceuticals Inc|AGIO - Analyst Median Target
- market capitalization data:
Market Value Agios Pharmaceuticals, Inc.|AGIO - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Agios Pharmaceuticals|AGIO - Net Asset Value|Market Capitalization to Book Value Ratio agios.com|AGIO - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Agios Pharmaceuticals|AGIO - Long-Term Debt to Capital|Short-Term Debt to Equity Agios Pharmaceuticals, Inc.|AGIO - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Agios Pharmaceuticals, Inc.
Fundamental company valuation:Agios Pharmaceuticals Inc - AGIO
Manufactured products of Agios Pharmaceuticals, Inc.

Investors seek a balance between asset quality and market price. This indicator reflects the equity per share, excluding speculative noise. For Agios Pharmaceuticals (AGIO), this metric demonstrates the efficiency of capitalizing rare disease development costs into actual net assets. The trend captures the transformation of investments into patents and intellectual property. By analyzing the book value per share, one can assess the intrinsic value of the business.

Competitors of Agios Pharmaceuticals (AGIO)

Book Value per Share ASND (Ascendis Pharma Inc.)|MDGL: Net Assets per Share|Net Assets per Single Share CORT|RYTM (rhythmtx.com) - Net Asset Value per Share|Net Assets per Single Share Akero AKRO|Share Book Value Metsera, Inc.|MoonLake Pharma (MLTX) - Book Value per Share|Accounting Value of a Share Crinetics Corp (CRNX)|Book Value per Share NAMS (NewAmsterdam Pharma)|soleno.life - Book Value per Share|Net Assets per Single Share Amicus Therapeutics, Inc. (FOLD)|ETNB: Accounting Value of a Share|GPCR (Structure Pharma) - Net Assets per Single Share|MiMedx Corp (MDXG) - Accounting Value per Share|RZLT (Rezolute, Inc.) - Book Value per Share|Book Value per Share lexpharma.com (LXRX)|MBX Biosciences (MBX) - Accounting Value per Share|Accounting Value of a Share ALT (Altimmune Inc)|Aardvark Therapeutics Corp - Net Assets per Single Share|Accounting Value per Share Sagimet Biosciences Inc SGMT|BIOA (BioAge Labs, Inc.) - Book Value per Share|biomeafusion.com (BMEA) - Net Asset Value per Share|QNCX - Accounting Value per Share|Fractyl Health Inc. (GUTS) - Book Price of a Share|VTVT (vTv Therapeutics, Inc.) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share Pluri Inc. (PLUR)|Net Assets per Single Share SYBX (synlogictx.com)|LPCN: Net Assets per Single Share|Matinas BioPharma Holdings, Inc. - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS